| Dr Anthony C Falvello, DO | |
|
1250 S Cedar Crest Blvd Ste 110, Allentown, PA 18103-6224 | |
| (610) 402-8900 | |
| Not Available |
| Full Name | Dr Anthony C Falvello |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 19 Years |
| Location | 1250 S Cedar Crest Blvd Ste 110, Allentown, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124227236 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | C2-0012824 (Delaware) | Secondary |
| 207X00000X | Orthopaedic Surgery | OS015140 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lehigh Valley Home Care Hazleton | Hazleton, PA | Home health agency |
| All Care Home Care, Inc | Hazleton, PA | Home health agency |
| Lehigh Valley Hospital - Hazleton | Hazleton, PA | Hospital |
| Lehigh Valley Hospital | Allentown, PA | Hospital |
| St Luke's Miners Memorial Hospital | Coaldale, PA | Hospital |
| Schuylkill Medical Center - South Jackson Street | Pottsville, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hazleton Professional Services | 8022110402 | 129 |
| Lehigh Valley Physician Group | 3072425123 | 1763 |
News Archive
ChemoCentryx, Inc., today announced that it reported positive preclinical and Phase I study results at the European Association for the Study of Diabetes (EASD). CCX140, a novel, orally bioavailable small molecule antagonist of the chemokine receptor CCR2, improved metabolic function while significantly reducing inflammatory macrophages found in adipose tissue in an animal model, and was well tolerated in Phase I clinical trials.
XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, reported positive data today from a phase 1 trial of XEN-D0103 administered orally.
The objective of the survey was two-sided. On one side, we wanted to better understand needs, concerns and attitudes of people with UC in an effort to identify solutions to improve the management of the disease. On the other, we wanted to build a questionnaire that could be used by HCPs to help define patients' needs and concerns.
SuperGen Inc. announced today that the Food and Drug Administration (FDA) has officially accepted the Orathecin™ (rubitecan) capsules' New Drug Application (NDA) for filing. Orathecin, an investigational anticancer compound, is an oral chemotherapy agent that has been investigated as a treatment for pancreatic cancer patients who have failed at least one prior chemotherapy.
› Verified 8 days ago
| Entity Name | Lehigh Valley Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457309650 PECOS PAC ID: 3072425123 Enrollment ID: O20040227000335 |
News Archive
ChemoCentryx, Inc., today announced that it reported positive preclinical and Phase I study results at the European Association for the Study of Diabetes (EASD). CCX140, a novel, orally bioavailable small molecule antagonist of the chemokine receptor CCR2, improved metabolic function while significantly reducing inflammatory macrophages found in adipose tissue in an animal model, and was well tolerated in Phase I clinical trials.
XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, reported positive data today from a phase 1 trial of XEN-D0103 administered orally.
The objective of the survey was two-sided. On one side, we wanted to better understand needs, concerns and attitudes of people with UC in an effort to identify solutions to improve the management of the disease. On the other, we wanted to build a questionnaire that could be used by HCPs to help define patients' needs and concerns.
SuperGen Inc. announced today that the Food and Drug Administration (FDA) has officially accepted the Orathecin™ (rubitecan) capsules' New Drug Application (NDA) for filing. Orathecin, an investigational anticancer compound, is an oral chemotherapy agent that has been investigated as a treatment for pancreatic cancer patients who have failed at least one prior chemotherapy.
› Verified 8 days ago
| Entity Name | Hazleton Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952464638 PECOS PAC ID: 8022110402 Enrollment ID: O20070305000195 |
News Archive
ChemoCentryx, Inc., today announced that it reported positive preclinical and Phase I study results at the European Association for the Study of Diabetes (EASD). CCX140, a novel, orally bioavailable small molecule antagonist of the chemokine receptor CCR2, improved metabolic function while significantly reducing inflammatory macrophages found in adipose tissue in an animal model, and was well tolerated in Phase I clinical trials.
XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, reported positive data today from a phase 1 trial of XEN-D0103 administered orally.
The objective of the survey was two-sided. On one side, we wanted to better understand needs, concerns and attitudes of people with UC in an effort to identify solutions to improve the management of the disease. On the other, we wanted to build a questionnaire that could be used by HCPs to help define patients' needs and concerns.
SuperGen Inc. announced today that the Food and Drug Administration (FDA) has officially accepted the Orathecin™ (rubitecan) capsules' New Drug Application (NDA) for filing. Orathecin, an investigational anticancer compound, is an oral chemotherapy agent that has been investigated as a treatment for pancreatic cancer patients who have failed at least one prior chemotherapy.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Anthony C Falvello, DO 1605 N Cedar Crest Blvd Ste 411, Allentown, PA 18104-2323 Ph: (570) 501-6368 | Dr Anthony C Falvello, DO 1250 S Cedar Crest Blvd Ste 110, Allentown, PA 18103-6224 Ph: (610) 402-8900 |
News Archive
ChemoCentryx, Inc., today announced that it reported positive preclinical and Phase I study results at the European Association for the Study of Diabetes (EASD). CCX140, a novel, orally bioavailable small molecule antagonist of the chemokine receptor CCR2, improved metabolic function while significantly reducing inflammatory macrophages found in adipose tissue in an animal model, and was well tolerated in Phase I clinical trials.
XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, reported positive data today from a phase 1 trial of XEN-D0103 administered orally.
The objective of the survey was two-sided. On one side, we wanted to better understand needs, concerns and attitudes of people with UC in an effort to identify solutions to improve the management of the disease. On the other, we wanted to build a questionnaire that could be used by HCPs to help define patients' needs and concerns.
SuperGen Inc. announced today that the Food and Drug Administration (FDA) has officially accepted the Orathecin™ (rubitecan) capsules' New Drug Application (NDA) for filing. Orathecin, an investigational anticancer compound, is an oral chemotherapy agent that has been investigated as a treatment for pancreatic cancer patients who have failed at least one prior chemotherapy.
› Verified 8 days ago
Mitchell E Cooper, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1250 S Cedar Crest Blvd, Suite 110, Allentown, PA 18103 Phone: 610-435-1003 Fax: 610-435-3184 | |
Lawrence E Weiss, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 250 Cetronia Rd, Allentown, PA 18104 Phone: 610-973-6200 Fax: 866-644-0894 | |
Thomas D Dibenedetto, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1250 S Cedar Crest Blvd, Suite 110, Allentown, PA 18103 Phone: 610-435-1003 Fax: 610-435-3184 | |
Robert C. Palumbo, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 250 Cetronia Road, Suite 303, Allentown, PA 18104 Phone: 610-973-6200 Fax: 610-973-6546 | |
Stephen P Falatyn, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 250 Cetronia Road, Suite 303, Allentown, PA 18104 Phone: 610-973-6200 Fax: 610-973-6546 | |
Dr. Gabriel Edward Lewullis, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1250 S Cedar Crest Blvd, Suite 110, Allentown, PA 18103 Phone: 610-402-8900 Fax: 610-402-5656 |